Abstract
Objective: The burden of obesity-related cancer has rarely been investigated. This study aims to investigate the trends of incidence of obesity-related cancer in a Chinese population. Method: During 2007-2021, a population-based registry of cancer covering 14.14 million people was performed in 207 medical sites by the Beijing Municipal Health Commission Information Center. We compared the trends of incidence of obesity-related cancers and non-obesity-related cancer. Results: Overall, there were 651,482 incident cancer patients in this population from 2007 to 2021. Of these patients, 48.49% were obesity-related cancers. For all obesity-related cancers combined, the age-standardized incidence rates (ASR) showed a significant upward trend (3.6% per year, P< 0.001). Conversely, for non-obesity-related cancers, the ASR was stable during this period (Fig.1 Age-specific differences of all cancers: A,B: annual changes; C,D: incidence rate ratio; E,F: incidence). We predict that the ASR for obesity-related cancers will increase 2.62-fold in 2035 compared to 2021, and will increase mainly in people younger than 50 and decrease in those over 75 years. Conclusion: Obesity-related cancer incidence significantly increased from 2007 to 2021. While most cases were diagnosed in old people, the obesity-related incidence increased sharply in young adults. These will increase the burden of cancer in the future. Disclosure J.Yang: None. C.Liu: None. Y.Yuan: None. Funding National Natural Science Foundation of China (81930019)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.